↓ Skip to main content

Dove Medical Press

Article Metrics

Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects

Overview of attention for article published in OncoTargets and therapy, July 2012
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
1 tweeter
patent
2 patents

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
27 Mendeley
Title
Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects
Published in
OncoTargets and therapy, July 2012
DOI 10.2147/ott.s32559
Pubmed ID
Authors

Beverly Barton, Beverly Barton

Abstract

In 2012, prostate cancer will once again be the second-leading cause of cancer death of American males. Although initially treatable, prostate cancer can recur in a hormone refractory form that is not responsive to current available therapies. The mortality rate associated with hormone refractory prostate cancer is high, and there is an urgent need for new therapeutic agents to treat prostate cancer. A common feature of prostate cancer is the dependence on activated signal transducer and activator of transcription 3 (STAT3), a transcription factor, for survival. More important, inhibition of STAT3 has been shown to induce apoptosis in prostate cancer cells. In recent years, inhibitors of STAT3 have emerged as promising molecular candidates for targeted prostate cancer therapy. The aim of this review is to examine the role of STAT3 in prostate cancer and how inhibitors of STAT3 could advance the quest for treatment of the disease. Janus kinase 2 (JAK2)-targeted therapy appears very promising in the treatment of prostate cancer. It has been shown to decrease symptoms associated with myeloproliferative disorders and increase overall survival of patients compared with the best available therapy. In addition to improved outcome, many JAK2 inhibitors have been found to be tolerable with no adverse impact on quality of life. As such, JAK2 inhibitors may play an important role in the management of patients with prostate cancer. Current studies are evaluating the role of JAK2 inhibitors in solid tumors. Pending clinical trial results will determine the future direction of JAK2 inhibitors in the treatment of patients with prostate cancer.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 4%
United States 1 4%
Unknown 25 93%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 30%
Researcher 8 30%
Other 2 7%
Student > Postgraduate 2 7%
Student > Doctoral Student 2 7%
Other 3 11%
Unknown 2 7%
Readers by discipline Count As %
Agricultural and Biological Sciences 15 56%
Medicine and Dentistry 5 19%
Chemistry 2 7%
Neuroscience 1 4%
Biochemistry, Genetics and Molecular Biology 1 4%
Other 0 0%
Unknown 3 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 February 2020.
All research outputs
#5,101,747
of 16,995,670 outputs
Outputs from OncoTargets and therapy
#216
of 2,442 outputs
Outputs of similar age
#38,388
of 132,921 outputs
Outputs of similar age from OncoTargets and therapy
#1
of 10 outputs
Altmetric has tracked 16,995,670 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 2,442 research outputs from this source. They receive a mean Attention Score of 2.2. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 132,921 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them